ProfileGDS5678 / 1420545_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 77% 75% 75% 73% 74% 76% 71% 74% 72% 74% 74% 74% 75% 75% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.2445777
GSM967853U87-EV human glioblastoma xenograft - Control 24.9883975
GSM967854U87-EV human glioblastoma xenograft - Control 34.9429175
GSM967855U87-EV human glioblastoma xenograft - Control 44.8663973
GSM967856U87-EV human glioblastoma xenograft - Control 54.8541474
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.9753276
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4833571
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.8848374
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6509572
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8969974
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.8874874
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8221774
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.9634575
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8951275